key: cord-0724227-7zgm2rkr authors: Lledó, Gema M.; Sellares, Jacobo; Brotons, Carlos; Sans, Mireia; Díez Antón, Juana M.; Blanco, Julià; Bassat, Quique; Sarukhan, Adelaida; Miró, José M.; de Sanjosé, Silvia title: Post-acute COVID-19 syndrome (PACS): a new tsunami requiring a universal case definition date: 2021-11-24 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2021.11.015 sha: 8cd35e5af41c787c808e5b0c2146b5bdbe1776ff doc_id: 724227 cord_uid: 7zgm2rkr nan *Equivalent merits as first author. 28 The SARS-CoV-2 pandemic has led to severe socio-economic and health impacts with 38 few comparable precedents in the contemporary era. In addition to the acute and 39 dramatic outcomes, the longer-term consequences have become a challenge. 40 According to current data, 80% of COVID-19 patients develop a mild or moderate 41 disease (1), 15% a severe disease and 5% a critical disease with different complications 42 such as acute respiratory distress syndrome (ARDS), sepsis and septic shock, 43 thromboembolism and multi-organ failure. When compared to influenza, there are 44 many differences in terms of clinical features, morbidity and mortality (2) where the term "post-COVID-19 condition" has been proposed to describe "individuals 77 J o u r n a l P r e -p r o o f with a history of probable or confirmed SARS-CoV-2 infection, usually three months 78 from the onset of COVID-19 with symptoms and that last for at least two months and 79 cannot be explained by an alternative diagnosis". Despite this suggestion and many 80 others previously ["prolonged COVID-19", "prolonged sequelae", "post-acute COVID-81 19", "post-acute COVID-19 Syndrome (PACS)" "persistent COVID-19 symptoms", "post-82 COVID-19 manifestations", "long-term COVID-19 effects", "post-COVID-19 syndrome", 83 "post-acute COVID-19 sequelae", "chronic COVID syndrome"], we have considered 84 formulate a final wording of the case definition as part of the consensus of the 85 Spanish-based Multidisciplinary Collaborative Group for the Scientific Monitoring of 86 COVID-19 (GCMSC), which provides a comprehensive overview of the symptoms 87 associated to SARS-CoV-2 after the acute phase (15). 88 89 We support the term "Post-Acute-COVID-19 Syndrome" or "PACS" as the best 90 approach to defining the clinical situation in which symptoms persist beyond four 91 weeks. However, two scenarios should be differentiated: Long COVID and Sequelae 92 (Supplementary Figure 1) The neurological manifestations, which are possibly the most challenging, include the 119 prolongation of disturbances in smell and taste, persistent headaches and a more 120 complex symptomatology related to autonomic dysfunction and neurocognitive 121 impairment. The latter has become one of the main complaints in terms of having the 122 greatest impact on patients' quality of life. Suddenly they experience difficulties in 123 carrying out otherwise routine tasks, performing work-related tasks or memorising 124 information. Consequently, many have been forced to leave their employment, facing 125 the additional aggravating uncertainty of an unknown duration of symptoms. 126 The underlying cause of the persistence of symptoms has yet to be established, but 128 many theories have been hypothesised. They mainly address virus-specific 129 pathophysiological changes, aberrant immune responses and inflammatory damage in 130 response to the acute infection (18) and mechanisms of viral persistence (19, 20) . More 131 recently, the roles of exosomes (21) and the intervention of mast cells (22) have also 132 come under consideration. These potential underlying etiological causes must be 133 explored if we are to improve our understanding of the mechanisms contributing to 134 the pathophysiology of PACS. The ambiguity regarding PACS risk factors, due to 135 variations in reporting, study design and clinical and demographic characteristics of 136 participants, is currently the main problem. However, female sex, high numbers of 137 symptoms and antibodies to SARS-CoV-2 may play a role in pathogenesis, although 138 some studies have found no significant differences. New lines of research investigate 139 specific biomarkers to establish clusters for both severe COVID-19 and PACS using 140 machine learning techniques to resolve the discrepancies addressed above (23) . We 141 must ensure the follow up of these patients, with a view to finding out how long these 142 symptoms persist and whether they develop into chronic disorders. These conditions 143 can lead to hospital readmission, estimated at around 3.6-4.5% in the first 30 days 144 (24, 25) and up to 27% after six months (26) The bulk of contributions should be allocated to where help is most needed, and it is 174 therefore imperative that international collaborative programmes be established if we 175 are to avoid inequality and non-homogenous access to care. 176 Although we can look forward to these advances, we must first identify patients with 177 these persisting symptoms, foster adequate monitoring and follow-up. We need to 178 advocate the establishment of a clear, standardised set of definitions and an 179 associated code, i.e., using the international classification of diseases (ICD) or 180 equivalent and be able to establish well-defined and consensual referral circuits 181 between primary and hospital care through a framework that allows for a dynamic, 182 coordinated and transversal flow of patients according to the severity of symptoms 183 and sequels. Depending on a country's resources, it may be necessary to create new 184 and complementary multidisciplinary units to provide support, as in the UK and US 185 examples, but estimating the cost is difficult as each country has its own health system 186 and its own budget. Furthermore, harmonised national and international registries will 187 be essential, which in turn will facilitate the identification and eventual inclusion of 188 patients in future clinical trials and research projects. The collaborative participation of 189 patients will help them to feel accompanied and not abandoned by the health system. 190 Finally, the full involvement of national health institutions will also be indispensable in 191 this fundamental task. Josep M. Miró (infectologist Quique Bassat (pediatrician, ICREA researcher at ISGlobal) Campins (epidemiologist, Hospital Vall d'Hebron), Robert Guerri (internist, Hospital del Mar Juana Díez (virologist, CEXS Mireia Sans 205 (family physician, CAP Borrell), and Adelaida Sarukhan Additionally, Antoni Plasència and Josep M Antó (ISGlobal) work as associated One-year outcomes in survivors of the acute respiratory distress 280 syndrome Clinical_case_definition-2021.1 285 286 15 The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases 289 (COVID-19) d China More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-295 :rs.3.rs-266574 COVID-19 syndrome COVID-19-related anosmia is associated with viral 305 persistence and inflammation in human olfactory epithelium and brain infection in hamsters Evolution of 310 antibody immunity to SARS-CoV-2 On the potential role of exosomes in 314 the COVID-19 reinfection/reactivation opportunity Covid-19 hyperinflammation and post-Covid-19 319 illness may be rooted in mast cell activation syndrome Immune-Based Prediction of COVID-19 Severity and Chronicity 324 Decoded Using Machine Learning. Front Immunol Characterization of Patients Who Return to Hospital Following Discharge from 330 Hospitalization for COVID-19 Assessment of thirty-day readmission rate, timing, causes and predictors after hospitalization 335 with COVID-19 6-month mortality and readmissions of hospitalized COVID-19 340 patients: A nationwide cohort study of 8,679 patients in Germany Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series Long covid-mechanisms, risk factors, and 350 management An integrated multidisciplinary model of 356 COVID-19 recovery care Tracking 360 development assistance for health and for COVID-19: a review of development assistance, 361 government, out-of-pocket, and other private spending on health for 204 countries and 362 territories